207 related articles for article (PubMed ID: 34613998)
1. In silico identification of natural product inhibitors against Octamer-binding transcription factor 4 (Oct4) to impede the mechanism of glioma stem cells.
Nayak C; Singh SK
PLoS One; 2021; 16(10):e0255803. PubMed ID: 34613998
[TBL] [Abstract][Full Text] [Related]
2. Linker length and composition influence the flexibility of Oct-1 DNA binding.
van Leeuwen HC; Strating MJ; Rensen M; de Laat W; van der Vliet PC
EMBO J; 1997 Apr; 16(8):2043-53. PubMed ID: 9155030
[TBL] [Abstract][Full Text] [Related]
3. The DNA binding specificity of the bipartite POU domain and its subdomains.
Verrijzer CP; Alkema MJ; van Weperen WW; Van Leeuwen HC; Strating MJ; van der Vliet PC
EMBO J; 1992 Dec; 11(13):4993-5003. PubMed ID: 1361172
[TBL] [Abstract][Full Text] [Related]
4. Solution structure of the POU-specific DNA-binding domain of Oct-1.
Dekker N; Cox M; Boelens R; Verrijzer CP; van der Vliet PC; Kaptein R
Nature; 1993 Apr; 362(6423):852-5. PubMed ID: 8479524
[TBL] [Abstract][Full Text] [Related]
5. An invariant asparagine in the POU-specific homeodomain regulates the specificity of the Oct-2 POU motif.
Botfield MC; Jancso A; Weiss MA
Biochemistry; 1994 Jul; 33(26):8113-21. PubMed ID: 7912957
[TBL] [Abstract][Full Text] [Related]
6. Critical POU domain residues confer Oct4 uniqueness in somatic cell reprogramming.
Jin W; Wang L; Zhu F; Tan W; Lin W; Chen D; Sun Q; Xia Z
Sci Rep; 2016 Feb; 6():20818. PubMed ID: 26877091
[TBL] [Abstract][Full Text] [Related]
7. POU domain factors in neural development.
Schonemann MD; Ryan AK; Erkman L; McEvilly RJ; Bermingham J; Rosenfeld MG
Adv Exp Med Biol; 1998; 449():39-53. PubMed ID: 10026784
[TBL] [Abstract][Full Text] [Related]
8. Solution structure of a POU-specific homeodomain: 3D-NMR studies of human B-cell transcription factor Oct-2.
Sivaraja M; Botfield MC; Mueller M; Jancso A; Weiss MA
Biochemistry; 1994 Aug; 33(33):9845-55. PubMed ID: 7914745
[TBL] [Abstract][Full Text] [Related]
9. The embryonic type of SPP1 transcriptional regulation is re-activated in glioblastoma.
Kijewska M; Kocyk M; Kloss M; Stepniak K; Korwek Z; Polakowska R; Dabrowski M; Gieryng A; Wojtas B; Ciechomska IA; Kaminska B
Oncotarget; 2017 Mar; 8(10):16340-16355. PubMed ID: 28030801
[TBL] [Abstract][Full Text] [Related]
10. Solution structure of the Oct-1 POU homeodomain determined by NMR and restrained molecular dynamics.
Cox M; van Tilborg PJ; de Laat W; Boelens R; van Leeuwen HC; van der Vliet PC; Kaptein R
J Biomol NMR; 1995 Jul; 6(1):23-32. PubMed ID: 7663141
[TBL] [Abstract][Full Text] [Related]
11. Bipartite DNA recognition by the human Oct-2 POU domain: POUs-specific phosphate contacts are analogous to those of bacteriophage lambda repressor.
Botfield MC; Weiss MA
Biochemistry; 1994 Mar; 33(9):2349-55. PubMed ID: 8117693
[TBL] [Abstract][Full Text] [Related]
12. JMJD3 suppresses stem cell-like characteristics in breast cancer cells by downregulation of Oct4 independently of its demethylase activity.
Xun J; Wang D; Shen L; Gong J; Gao R; Du L; Chang A; Song X; Xiang R; Tan X
Oncotarget; 2017 Mar; 8(13):21918-21929. PubMed ID: 28423536
[TBL] [Abstract][Full Text] [Related]
13. Stem cell markers in glioma progression and recurrence.
Hattermann K; Flüh C; Engel D; Mehdorn HM; Synowitz M; Mentlein R; Held-Feindt J
Int J Oncol; 2016 Nov; 49(5):1899-1910. PubMed ID: 27600094
[TBL] [Abstract][Full Text] [Related]
14. Coactivator OBF-1 makes selective contacts with both the POU-specific domain and the POU homeodomain and acts as a molecular clamp on DNA.
Sauter P; Matthias P
Mol Cell Biol; 1998 Dec; 18(12):7397-409. PubMed ID: 9819426
[TBL] [Abstract][Full Text] [Related]
15. ISG15 enhances glioma cell stemness by promoting Oct4 protein stability.
Dai Y; Yu T; Yu C; Lu T; Zhou L; Cheng C; Ni H
Environ Toxicol; 2022 Sep; 37(9):2133-2142. PubMed ID: 35506701
[TBL] [Abstract][Full Text] [Related]
16. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein.
Ikushima H; Todo T; Ino Y; Takahashi M; Saito N; Miyazawa K; Miyazono K
J Biol Chem; 2011 Dec; 286(48):41434-41441. PubMed ID: 21987575
[TBL] [Abstract][Full Text] [Related]
17. Control of glioma cell death and differentiation by PKM2-Oct4 interaction.
Morfouace M; Lalier L; Oliver L; Cheray M; Pecqueur C; Cartron PF; Vallette FM
Cell Death Dis; 2014 Jan; 5(1):e1036. PubMed ID: 24481450
[TBL] [Abstract][Full Text] [Related]
18. Novel function of MDA-9/Syntenin (SDCBP) as a regulator of survival and stemness in glioma stem cells.
Talukdar S; Das SK; Pradhan AK; Emdad L; Shen XN; Windle JJ; Sarkar D; Fisher PB
Oncotarget; 2016 Aug; 7(34):54102-54119. PubMed ID: 27472461
[TBL] [Abstract][Full Text] [Related]
19. RhoGDIα suppresses self-renewal and tumorigenesis of glioma stem cells.
Wu F; Hu P; Li D; Hu Y; Qi Y; Yin B; Jiang T; Yuan J; Han W; Peng X
Oncotarget; 2016 Sep; 7(38):61619-61629. PubMed ID: 27557508
[TBL] [Abstract][Full Text] [Related]
20. The POU-specific domain of Pit-1 is essential for sequence-specific, high affinity DNA binding and DNA-dependent Pit-1-Pit-1 interactions.
Ingraham HA; Flynn SE; Voss JW; Albert VR; Kapiloff MS; Wilson L; Rosenfeld MG
Cell; 1990 Jun; 61(6):1021-33. PubMed ID: 2350782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
